Boehringer Ingelheim: BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES
Boehringer Ingelheim gains exclusive global rights to a panel of cancer-specific antibodies to enable the development of targeted cancer therapies These engineered antibodies may allow for
Reinhard Malin Damian Oconnell Cliver Wood Agency For Science Innovation Unit Communications Boehringer Ingelheim
Source: finanznachrichten.de